Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 15/20 | 0.80 |
| ▸ | USP47 | Q96K76 | 7/20 | 0.80 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.56 |
| ▸ | USP10 | Q14694 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.45 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2680726 | 0.89 | USP7 (1.00) | USP7USP47PADI4USP10IDO1 | |
| SCHEMBL2681525 | 0.88 | USP7 (0.77) | USP7USP47PADI4USP10IDO1 | |
| SCHEMBL2680096 | 0.81 | USP7 (0.80) | USP7USP47PADI4USP10 | |
| SCHEMBL2680832 | 0.81 | USP7 (0.67) | USP7USP47PADI4USP10PDE7A | |
| SCHEMBL2681330 | 0.81 | USP7 (0.70) | USP7USP47PADI4USP10LMNA | |
| SCHEMBL2680950 | 0.81 | USP7 (0.66) | USP7USP47PADI4IDO1PDE7A | |
| SCHEMBL2681219 | 0.80 | USP7 (0.79) | USP7USP47PADI4 | |
| SCHEMBL2680133 | 0.79 | USP7 (0.63) | USP7USP47PADI4IDO1PDE7A | |
| SCHEMBL2679916 | 0.78 | USP7 (1.00) | USP7USP47PADI4USP10IDO1 | |
| SCHEMBL3717082 | 0.78 | USP7 (0.76) | USP7USP47PADI4IDO1PDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680139-B2 | Anti-neoplastic compounds, compositions and methods | PROGENRA (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA | 2012-05-10 | — | — | US | disclosed |
| WO-2010114881-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA INC. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | SERPINB1, TP53, CTSE | USP7 437/4885USP47 315/4885PADI4 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.